AI-enabled IntelliSep uses sophisticated high-speed cameras and microfluidics to analyze the reaction of white blood cells from a patient showing signs and symptoms of sepsis. Using a standard blood ...
SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- A new peer-reviewed study published in JACEP Open found that providing emergency department (ED) physicians with IntelliSep® sepsis test results was ...
SAN FRANCISCO--(BUSINESS WIRE)--Cytovale, a medical diagnostics company focused on providing a faster, more insightful way to diagnose fast-moving and immune mediated diseases, today announced the ...
Data Published in Journal PLOS ONE Demonstrates Investigational IntelliSep test may Provide Useful Prognostic Information for Patients with Suspected Infection SAN FRANCISCO--(BUSINESS WIRE)--Cytovale ...
Cytovale Inc. has posted a feverish run of wins lately. The company gained U.S. FDA clearance for its Intellisep rapid test for sepsis in January 2023, raised $84 million in a series C in November and ...
SAN FRANCISCO and CHICAGO, March 23, 2026 /PRNewswire/ -- Cytovale® today announced new multicenter, real-world data demonstrating that clinical and operational improvements in sepsis care first ...
Cytovale has developed a FDA-cleared, rapid diagnostic tool for sepsis, and it just raised $100 million to roll it out to hospital systems across the country. Every year, over 1.7 million Americans ...
Cytovale's IntelliSep ® rapid sepsis test spotlighted for its innovative approach to sepsis care and demonstrated real-world impact in helping hospitals save lives SAN FRANCISCO and CHICAGO, Jan. 12, ...
Sepsis is the leading cause of death worldwide according to the World Health Organization, killing 11 million people each year, many of them children, and disabling many more. But while speedy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results